Budigalimab (ABBV 181; PR 1648817) 是一种人源 IgG1 单克隆抗体,靶向程序性细胞死亡 1 (PD-1) 受体。Budigalimab 具有 Fc 突变,从而减少了 Fc 受体相互作用和效应因子的抑制作用。
生物活性 | Budigalimab (ABBV 181; PR 1648817) is a humanizedIgG1monoclonal antibody targetingprogrammed cell death 1(PD-1)receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function[1]. |
IC50& Target | programmed cell death 1 (PD-1) receptor[1] |
CAS 号 | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |